Latest Europe News

Little Green Pharma (ASX:LGP) has completed its merger with Cannatrek, creating a dominant player in Australia and Europe’s medicinal cannabis market with a majority stake held by former Cannatrek shareholders.

4DMedical has leapfrogged into the European lung health market by acquiring Austrian AI imaging firm contextflow, gaining immediate commercial presence and a CE-marked lung cancer screening solution.

Regener8 Resources has completed its acquisition of the Srebrenica North polymetallic project in Bosnia and Herzegovina and is mobilising initial exploration activities to target drill-ready prospects.

Harvest Technology Group has appointed Veronica Bainton as CEO, signalling a sharpened focus on defence markets and scaling its Nodestream platform internationally.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

4DMedical has landed a three-year commercial contract with SimonMed Imaging, deploying its CT:VQ™ technology across more than 170 US outpatient centres, marking a significant step in its US market expansion.

KTEK Aerosystems has restarted deliveries after Middle East conflict-related supply chain disruptions, shipping an initial A$500,000 order and aiming for 150 units per month within five months.

Advanced Energy Minerals (ASX:AEM) is ramping up its Cap-Chat high purity alumina production, targeting 3,000 tpa by mid-2026 and planning to double capacity to 6,000 tpa by 2029 amid a forecast supply deficit and surging demand.

EcoGraf confirms its patented HFfree process offers competitive costs for producing high-purity spherical graphite, targeting non-Chinese battery supply chains with plans for facilities in the US, Europe, and Asia.

Champion Iron Limited reported a 19% increase in net profit to C$168.7 million for FY2026, driven by record production and sales, progress on its DRPF project, and the strategic acquisition of Rana Gruber.

Actinogen Medical has obtained positive scientific advice from the European Medicines Agency that aligns with prior FDA guidance, clarifying regulatory requirements for its Alzheimer’s drug Xanamem and paving the way for a streamlined approval process in major markets.

OncoSil Medical has secured a pivotal ethics committee approval in Italy, reclassifying its OSPRItaly registry and enabling a streamlined procurement process that could double the number of authorised hospitals using its OncoSil™ device by mid-2027.